GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Shares Outstanding (EOP)

BGLC (BioNexus Gene Lab) Shares Outstanding (EOP) : 1.80 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioNexus Gene Lab's shares outstanding for the quarter that ended in Mar. 2025 was 1.80 Mil.

BioNexus Gene Lab's quarterly shares outstanding stayed the same from Dec. 2024 (1.80 Mil) to Mar. 2025 (1.80 Mil).

BioNexus Gene Lab's annual shares outstanding increased from Dec. 2023 (1.77 Mil) to Dec. 2024 (1.80 Mil). It means BioNexus Gene Lab issued new shares from Dec. 2023 to Dec. 2024 .


BioNexus Gene Lab Shares Outstanding (EOP) Historical Data

The historical data trend for BioNexus Gene Lab's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Shares Outstanding (EOP) Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial 1.43 1.43 1.45 1.77 1.80

BioNexus Gene Lab Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.77 1.80 1.80 1.80

Competitive Comparison of BioNexus Gene Lab's Shares Outstanding (EOP)

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's Shares Outstanding (EOP) Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Shares Outstanding (EOP) falls into.


;
;

BioNexus Gene Lab Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


BioNexus Gene Lab  (NAS:BGLC) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BioNexus Gene Lab Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab Business Description

Traded in Other Exchanges
N/A
Address
No.5 Jln Bangsar Utama 1, Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200

BioNexus Gene Lab Headlines

From GuruFocus